{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:40:18Z","timestamp":1793108418424,"version":"4.5.0"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.00634","type":"journal-article","created":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T04:46:17Z","timestamp":1594874777000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":112,"title":["Immune Checkpoint Inhibitor-Induced Myasthenia Gravis"],"prefix":"10.3389","volume":"11","author":[{"given":"Yi-Te","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chih","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Chou","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Ting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Society for immunotherapy of cancer toxicity management working: managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e1365","DOI":"10.1212\/WNL.0000000000006278","article-title":"Pearls and oy-sters: pembrolizumab-induced myasthenia gravis","volume":"91","author":"Algaeed","year":"2018","journal-title":"Neurology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"E25","DOI":"10.1002\/mus.25496","article-title":"A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma","volume":"55","author":"Alnahhas","year":"2017","journal-title":"Muscle Nerve."},{"key":"B4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/CJI.0000000000000161","article-title":"Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder","volume":"40","author":"Chang","year":"2017","journal-title":"J Immunother."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e9262","DOI":"10.1097\/MD.0000000000009262","article-title":"Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e7350","DOI":"10.1097\/MD.0000000000007350","article-title":"Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine."},{"key":"B8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejca.2018.07.125","article-title":"Rituximab in the treatment of pembrolizumab-induced myasthenia gravis","volume":"102","author":"Crusz","year":"2018","journal-title":"Eur J Cancer."},{"key":"B9","doi-asserted-by":"publisher","first-page":"E120","DOI":"10.1002\/mus.26021","article-title":"Refractory myasthenia gravis exacerbation triggered by pembrolizumab","volume":"57","author":"Earl","year":"2018","journal-title":"Muscle Nerve."},{"key":"B10","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1159\/000479958","article-title":"Nivolumab-Induced myocarditis concomitant with myasthenia gravis","volume":"10","author":"Fukasawa","year":"2017","journal-title":"Case Rep Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","article-title":"Myasthenia triggered by immune checkpoint inhibitors: new case and literature review","volume":"27","author":"Gonzalez","year":"2017","journal-title":"Neuromuscul Disord."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e00355","DOI":"10.1002\/rcr2.355","article-title":"Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer","volume":"6","author":"Hibino","year":"2018","journal-title":"Respirol Case Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3988\/jcn.2018.14.1.115","article-title":"Emergence of myasthenia gravis with myositis in a patient treated with pembrolizumab for thymic cancer","volume":"14","author":"Huh","year":"2018","journal-title":"J Clin Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","article-title":"Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.amjoto.2018.06.003","article-title":"Immune checkpoint-mediated myositis and myasthenia gravis: a case report and review of evaluation and management","volume":"39","author":"Kang","year":"2018","journal-title":"Am J Otolaryngol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.25141","article-title":"Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab","volume":"54","author":"Lau","year":"2016","journal-title":"Muscle Nerve."},{"key":"B18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/mus.24648","article-title":"Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer","volume":"52","author":"Loochtan","year":"2015","journal-title":"Muscle Nerve."},{"key":"B20","first-page":"11","article-title":"Myasthenia gravis and rhabdomyolysis in a patient with advanced renal cell cancer treated with nivolumab: a case report and review of the literature","volume":"2","author":"Lopez","year":"2015","journal-title":"Br J Med Health Res"},{"key":"B21","first-page":"119","article-title":"Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis","volume":"78","author":"Maeda","year":"2016","journal-title":"Nagoya J Med Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer."},{"key":"B23","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/1078155216687389","article-title":"Pembrolizumab-induced myasthenia gravis: a fatal case report","volume":"24","author":"March","year":"2018","journal-title":"J Oncol Pharm Pract."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1702","DOI":"10.7759\/cureus.1702","article-title":"Myasthenia gravis induced by nivolumab: a case report","volume":"9","author":"Mehta","year":"2017","journal-title":"Cureus."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.2169\/internalmedicine.9153-17","article-title":"Relapsed myasthenia gravis after nivolumab treatment","volume":"57","author":"Mitsune","year":"2018","journal-title":"Intern Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/CMR.0000000000000310","article-title":"Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients","volume":"27","author":"Nguyen","year":"2017","journal-title":"Melanoma Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.2169\/internalmedicine.1956-18","article-title":"Pembrolizumab-induced ocular myasthenia gravis with anti-titin antibody and necrotizing myopathy","volume":"58","author":"Onda","year":"2019","journal-title":"Intern Med."},{"key":"B28","unstructured":"Pembrolizumab therapy triggering an exacerbation of preexisting autoimmune disease: a report of 2 patient cases2324709616674316\n            PhadkeSD\n            GhabourR\n            SwickBL\n            SwensonA\n            MilhemM\n            ZakhariaY\n          10.1177\/232470961667431627826593J Investig Med High Impact Case Rep.42016"},{"key":"B29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/mus.25163","article-title":"Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer","volume":"54","author":"Polat","year":"2016","journal-title":"Muscle Nerve."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ensci.2018.11.023","article-title":"Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: a life-threatening continuum of neuromuscular and cardiac toxicity","volume":"14","author":"Rota","year":"2019","journal-title":"eNeurologicalSci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/mus.25212","article-title":"Benign form of myasthenia gravis after nivolumab treatment","volume":"54","author":"Sciacca","year":"2016","journal-title":"Muscle Nerve."},{"key":"B32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/jjco\/hyv158","article-title":"Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma","volume":"46","author":"Shirai","year":"2016","journal-title":"Jpn J Clin Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1016\/j.jtho.2017.02.024","article-title":"Continued response to one dose of nivolumab complicated by myasthenic crisis and myositis","volume":"12","author":"Tan","year":"2017","journal-title":"J Thorac Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"omy094","DOI":"10.1093\/omcr\/omy094","article-title":"Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis","volume":"2018","author":"Tozuka","year":"2018","journal-title":"Oxf Med Case Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/mus.25055","article-title":"Myasthenia gravis exacerbation associated with pembrolizumab","volume":"54","author":"Zhu","year":"2016","journal-title":"Muscle Nerve."},{"key":"B36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer."},{"key":"B37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fneur.2018.00150","article-title":"Myasthenia gravis induced by ipilimumab in a patient with metastatic melanoma","volume":"9","author":"Montes","year":"2018","journal-title":"Front Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/CMR.0000000000000598","article-title":"Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma","volume":"29","author":"Mohn","year":"2019","journal-title":"Melanoma Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"101105","DOI":"10.1016\/j.eucr.2019.101105","article-title":"A case report of nivolumab-induced myasthenia gravis and myositis in a metastatic renal cell carcinoma patient","volume":"29","author":"Nakanishi","year":"2020","journal-title":"Urol Case Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"502","DOI":"10.5692\/clinicalneurol.cn-001251","article-title":"A case of myasthenia gravis and myositis induced by pembrolizumab","volume":"59","author":"Noda","year":"2019","journal-title":"Rinsho Shinkeigaku."},{"key":"B41","doi-asserted-by":"publisher","first-page":"E23","DOI":"10.1002\/mus.26640","article-title":"Diaphragm involvement in immune checkpoint inhibitor-related myositis","volume":"60","author":"Sekiguchi","year":"2019","journal-title":"Muscle Nerve."},{"key":"B42","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/CJI.0000000000000278","article-title":"Du thanh: myasthenia gravis induced by immune checkpoint inhibitors","volume":"42","author":"Becquart","year":"2019","journal-title":"J Immunother."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2539493","DOI":"10.1155\/2019\/2539493","article-title":"Severe myositis, myocarditis, and myasthenia gravis with elevated anti-striated muscle antibody following single dose of ipilimumab-nivolumab therapy in a patient with metastatic melanoma","volume":"2019","author":"Fazel","year":"2019","journal-title":"Case Rep Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2217\/imt-2017-0043","article-title":"Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review","volume":"9","author":"Hasegawa","year":"2017","journal-title":"Immunotherapy."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2217\/imt-2019-0106","article-title":"Myasthenia gravis induced by avelumab","volume":"11","author":"Yuen","year":"2019","journal-title":"Immunotherapy."},{"key":"B46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve."},{"key":"B47","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer."},{"key":"B49","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.ncl.2011.12.012","article-title":"Evaluation of neuromuscular junction disorders in the electromyography laboratory","volume":"30","author":"Juel","year":"2012","journal-title":"Neurol Clin"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. prevalence, clinical correlates, diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology."},{"key":"B51","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis","volume":"505","author":"Howard","year":"1987","journal-title":"Ann N Y Acad Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev Clin Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology."},{"key":"B54","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Ann Neurol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain."},{"key":"B56","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1600-0404.1995.tb00432.x","article-title":"Associated autoimmune diseases in myasthenia gravis. a population-based study","volume":"91","author":"Christensen","year":"1995","journal-title":"Acta Neurol Scand."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/00000441-200601000-00004","article-title":"High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: a clinical and serologic study","volume":"331","author":"Sthoeger","year":"2006","journal-title":"Am J Med Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/joim.12310","article-title":"The autoimmune spectrum of myasthenia gravis: a Swedish population-based study","volume":"277","author":"Fang","year":"2015","journal-title":"J Intern Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3109\/08916934.2015.1030614","article-title":"Complicating autoimmune diseases in myasthenia gravis: a review","volume":"48","author":"Nacu","year":"2015","journal-title":"Autoimmunity."},{"key":"B61","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s40425-019-0626-9","article-title":"Metastatic merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?","volume":"7","author":"Zaremba","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B62","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.nmd.2018.11.012","article-title":"Clinical spectrum of neuromuscular complications after immune checkpoint inhibition","volume":"29","author":"Puwanant","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"B63","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12883-019-1416-1","article-title":"Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report","volume":"19","author":"Kamo","year":"2019","journal-title":"BMC Neurol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.nmd.2019.10.006","article-title":"Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation","volume":"30","author":"Valenti-Azcarate","year":"2020","journal-title":"Neuromuscul Disord."},{"key":"B65","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B66","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res."},{"key":"B67","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1111\/jns.12339","article-title":"Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment","volume":"24","author":"Psimaras","year":"2019","journal-title":"J Peripher Nerv Syst."},{"key":"B68","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/mus.26676","article-title":"Trouble at the junction: when myopathy and myasthenia overlap","volume":"60","author":"Nicolau","year":"2019","journal-title":"Muscle Nerve."},{"key":"B69","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11926-019-0811-3","article-title":"Immune checkpoint inhibitor-induced myositis: a case report and literature review","volume":"21","author":"Kadota","year":"2019","journal-title":"Curr Rheumatol Rep."},{"key":"B70","doi-asserted-by":"publisher","first-page":"683","DOI":"10.7326\/L17-0396","article-title":"Survival after fulminant myocarditis induced by immune-checkpoint inhibitors","volume":"167","author":"Arangalage","year":"2017","journal-title":"Ann Inter Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","article-title":"Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors","volume":"18","author":"Kao","year":"2018","journal-title":"Curr Neurol Neurosci Rep."},{"key":"B72","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/1759-7714.13266","article-title":"Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related adverse reactions in the nervous system","volume":"11","author":"Shi","year":"2020","journal-title":"Thorac Cancer."},{"key":"B73","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer."},{"key":"B74","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/WCO.0000000000000686","article-title":"Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy","volume":"32","author":"Perrinjaquet","year":"2019","journal-title":"Curr Opin Neurol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1756286418799864","DOI":"10.1177\/1756286418799864","article-title":"Neurological complications of immune checkpoint inhibitors: what happens when you \u2018take the brakes off'the immune system","volume":"11","author":"Dalakas","year":"2018","journal-title":"Ther Adv Neurol Disord."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00634\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T04:46:22Z","timestamp":1594874782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00634\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":75,"alternative-id":["10.3389\/fneur.2020.00634"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.00634","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]},"article-number":"634"}}